No abstract

No abstract

Objective — to study the effectiveness of immunoglobulin therapy in patients with co-infection of drug-resistant tuberculosis (DR-TB)/HIV at the level of CD4+ lymphocytes from 200 to 50 cells/μl, based on a study of the dynamics of biochemical parameters. Materials and methods. The study involved 52 patients aged 20 to 55 years, with a mean age of (37.2 ± 7.8) years. All patients were HIV-positive with laboratory-confirmed DR-TB with mycobacterial resistance to first- and second-line drugs. Patients with DR-TB/HIV were distributed as follows: 1 group (control) — 26 patients with DR-TB/HIV, receiving standard treatment of second-line AMBP and ARVT; group 2 (main) — 26 patients with DR-TB/HIV, who also received standard treat­ment of second-line AMBP and ARVT, with the addition of complex therapy with intravenous immunoglobulin G (IgG). Results and discussion. Against the background of treatment, the dynamics of changes in biochemical parameters was as follows: patients in the control group, after the first 2 weeks of AMBP, there was an increase in intoxication load on the hepatobiliary and urinary systems, which led, on the one hand, to dysfunction liver with hyperbilirubinemia, increased transaminase activity, thymol turbidity, and on the other — to the development of renal failure with hypercreatininemia, hyperuricemia, azotemia and oliguria. As a result, timely appointment of ARVT (2 weeks after AMBP) in 19 (73.1 %) patients was impossible and was carried out much later than desired (after 2—3 months).Treatment of patients with comorbid pathology of DR-TB/HIV, which included complex intravenous IgG on the background of complex therapy, was accompanied by positive clinical and laboratory dynamics, which created conditions for ARVT involvement after the second week of complex therapy according to the developed treatment method. Conclusions. The use of immunologically targeted treatment with intravenous IgG made it possible to successfully prescribe ARVT to patients of the main group in 2 weeks from the start of AMBT, which is very useful to prevent adverse reactions, increase treatment efficacy and reduce mortality in patients with comorbid DR-TB/HIV in a state of deep immunosuppression.

Background: Treatment of the patients with multidrug-resistant tuberculosis (MDR-TB)/HIV coinfection in a state of severely suppressed immune system remains unsatisfactory. Methods: The study involved 52 HIV-positive patients with MDR-TB and CD4+ lymphocyte cells below 50 cells/μCL. Patients in control group (Group 1) and in basic group (Group 2) received standard treatment with second-line antituberculosis agents and antiretroviral agents. In addition, the patients in basic group were treated by immunoglobulin G (IgG) intravenously. Immunological diagnostics with the determination of the level of lymphocytes subgroups (CD3+, CD4+, CD8+, CD4+/CD8+) was carried out using an AQUIOS™ CL flow cytometry device at the beginning and after 3–20 months of treatment. Statistical analysis was performed using the Statistica 10.0 software (Stat. Soft Inc., USA). Results: In the patients of Group 2, the absolute number of CD3+ and CD4+ cells at the end of the 20th month of the treatment normalized in 26.9% (absolute amount) and 42.3% (relative amount) of subjects, while in Group 1, this indicator remained below the normal level (P < 0.05). The addition of IgG into standard therapy caused normalization of CD8+ count in 76.9% of patients, while in the control group-only in 46.2% of patients (P < 0.05). Conclusions: The administration of IgG in combination with standard anti-tuberculosis and antiretroviral therapy (ART) contributes to the normalization of the cellular immunity status in patients with MDR-TB/HIV coinfection and severe immunosuppression and allows you to start ART earlier than in patients with single standard therapy